Analyst Update: Apple, Navient, and OHR Pharma

Analysts adjusted their ratings on Apple Inc. (AAPL), Navient Corp (NAVI), and OHR Pharmaceutical Inc (OHRP)

Mar 2, 2015 at 11:38 AM
facebook X logo linkedin


Analysts are weighing in today on electronics maker Apple Inc. (NASDAQ:AAPL), educational loan concern Navient Corp (NASDAQ:NAVI), and pharmaceutical firm OHR Pharmaceutical Inc (NASDAQ:OHRP). Here's a quick look at today's brokerage notes on AAPL, NAVI, and OHRP.

  • The first week of March is already filled with news for AAPL, which is grappling with the unveiling of main competitor Samsung Electronics' latest smartphone, while heading to court over a $415 million settlement related to employee poaching. What's more, rumors that the company could be unveiling its new smartwatch as early as next week are picking up. Reacting to the news was Morgan Stanley, which raised its price target to $160 from $133 while underscoring an "overweight" rating, prompting the shares to add about 0.9% to reach $129.62. On the charts, Apple Inc. has added over 17% year-to-date, and call buying is popular in the options pits. Specifically, AAPL's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 2.42 sits in the 63rd percentile of its annual range.

  • This morning, NAVI was placed on the short-sale restricted list, after Barclays and Compass Point lowered their ratings on the security to "equal weight" and "neutral," respectively, from "overweight" and "buy." In response, the shares are down about 10.5% today to hit $19.17, adding up to an 11.3% year-to-date loss. Despite Navient Corp's technical woes, the brokerage bunch is firmly optimistic on the stock. All five covering analysts rate the security a "buy" or better, with four of them doling out lofty "strong buy" opinions.

  • Cowen and Company initiated coverage on OHRP with a price target of $25 and an "outperform" rating, following an encouraging mid-stage study of the company's squalamine eye drops. The price target represents a lofty 150.8% premium to the shares' current perch of $9.97. Today, the shares are up nearly 28.9%, adding up to a 18.7% year-to-date gain. Accordingly, call activity has been prominent in the stock's options pits, as OHR Pharmaceutical Inc's Schaeffer's put/call open interest ratio (SOIR) of 0.23 sits in the 15th percentile of all similar readings taken over the past year.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI